Lyra Therapeutics Management
Management criteria checks 2/4
Lyra Therapeutics' CEO is Maria Palasis, appointed in Jan 2015, has a tenure of 10.75 years. total yearly compensation is $3.73M, comprised of 16.7% salary and 83.3% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $51.11K. The average tenure of the management team and the board of directors is 3.4 years and 5.9 years respectively.
Key information
Maria Palasis
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 16.75% |
| CEO tenure | 10.8yrs |
| CEO ownership | 0.4% |
| Management average tenure | 3.4yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
Jun 16Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$39m |
| Mar 31 2025 | n/a | n/a | -US$80m |
| Dec 31 2024 | US$4m | US$625k | -US$93m |
| Sep 30 2024 | n/a | n/a | -US$98m |
| Jun 30 2024 | n/a | n/a | -US$101m |
| Mar 31 2024 | n/a | n/a | -US$69m |
| Dec 31 2023 | US$2m | US$583k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$60m |
| Dec 31 2022 | US$2m | US$583k | -US$55m |
| Sep 30 2022 | n/a | n/a | -US$55m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$48m |
| Dec 31 2021 | US$2m | US$552k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$4m | US$471k | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$843k | US$388k | -US$17m |
Compensation vs Market: Maria's total compensation ($USD3.73M) is above average for companies of similar size in the US market ($USD611.00K).
Compensation vs Earnings: Maria's compensation has increased whilst the company is unprofitable.
CEO
Maria Palasis (60 yo)
Dr. Maria Palasis, Ph D, is Independent Director of Beta Bionics, Inc. from January 29, 2025. She serves as Director at PanTher Therapeutics, Inc. since June 2021.Dr. Palasis has been Chief Executive Offi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 10.8yrs | US$3.73m | 0.44% $ 51.1k | |
| CFO, Treasurer & Secretary | 4.1yrs | US$1.30m | 0.21% $ 24.2k | |
| Co-Founder | no data | no data | no data | |
| Chief Legal Officer | 2yrs | no data | no data | |
| Senior Vice President of Clinical Affairs | no data | no data | no data | |
| Chief Clinical Advisor | 4.7yrs | no data | no data | |
| Senior Vice President of Quality | 2.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | no data | no data | |
| VP of Finance & Risk | no data | no data | no data |
Experienced Management: LYRA's management team is considered experienced (3.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Chairman | 10.8yrs | US$3.73m | 0.44% $ 51.1k | |
| Lead Independent Director | 3.6yrs | US$100.67k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$72.17k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$61.42k | 0.014% $ 1.6k | |
| Independent Director | 5yrs | US$62.73k | 0.0013% $ 147.3 |
Experienced Board: LYRA's board of directors are considered experienced (5.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 08:35 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lyra Therapeutics, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |